Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07QTG
|
|||
Former ID |
DIB018004
|
|||
Drug Name |
JNJ-479655
|
|||
Synonyms |
1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, > Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Clinical trial | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C28H32N4O2S
|
|||
Canonical SMILES |
C1COCCC1(CNC(=O)C2=C(N=CC=C2)SC3=CC=CC=C3)N4CCN(CC4)C5=CC=CC=C5
|
|||
InChI |
1S/C28H32N4O2S/c33-26(25-12-7-15-29-27(25)35-24-10-5-2-6-11-24)30-22-28(13-20-34-21-14-28)32-18-16-31(17-19-32)23-8-3-1-4-9-23/h1-12,15H,13-14,16-22H2,(H,30,33)
|
|||
InChIKey |
XREFXUCWSYMIOG-UHFFFAOYSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | P2X purinoceptor 7 (P2RX7) | Target Info | Antagonist | [2] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Reactome | The NLRP3 inflammasome | |||
WikiPathways | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways |
References | Top | |||
---|---|---|---|---|
REF 1 | The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci. 2013 Mar;53:52-62. | |||
REF 2 | Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.